Edition:
United Kingdom

Ultragenyx Pharmaceutical Inc (RARE.OQ)

RARE.OQ on NASDAQ Stock Exchange Global Select Market

47.26USD
5:10pm GMT
Change (% chg)

$-0.39 (-0.82%)
Prev Close
$47.65
Open
$47.89
Day's High
$48.30
Day's Low
$46.81
Volume
91,368
Avg. Vol
218,606
52-wk High
$91.17
52-wk Low
$41.68

Select another date:

BRIEF-Kyowa Kirin, Ultragenyx Announce Crysvita Receives Conditional Marketing Authorization In Europe For The Treatment Of X–Linked Hypophosphatemia In Children

* KYOWA KIRIN AND ULTRAGENYX ANNOUNCE CRYSVITA® (BUROSUMAB) RECEIVES CONDITIONAL MARKETING AUTHORIZATION IN EUROPE FOR THE TREATMENT OF X–LINKED HYPOPHOSPHATEMIA IN CHILDREN

BRIEF-Ultragenyx Reports Q4 Loss Per Share $1.89

* ULTRAGENYX REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND CORPORATE UPDATE

BRIEF-Ultragenyx Prices Public Offering Of 4.39 Mln Common Shares At $57/Share

* ULTRAGENYX ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Ultragenyx Announces Proposed Public Offering Of Common Stock

* ULTRAGENYX ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Capital International Investors Reports 10.3 Pct Passive Stake In Ultragenyx

* CAPITAL INTERNATIONAL INVESTORS REPORTS 10.3 PERCENT PASSIVE STAKE IN ULTRAGENYX PHARMACEUTICAL INC AS OF DECEMBER 29, 2017 - SEC FILING‍​ Source text for Eikon: (http://bit.ly/2D1HymY) Further company coverage:

BRIEF-Ultragenyx Announces Update To UX007 Development Program In Long-Chain Fatty Acid Oxidation Disorder Patients

* ULTRAGENYX ANNOUNCES UPDATE TO UX007 DEVELOPMENT PROGRAM IN LONG-CHAIN FATTY ACID OXIDATION DISORDER PATIENTS

BRIEF-Ultragenyx Sells Priority Review Voucher For $130 Mln

* ENTERED INTO A DEFINITIVE AGREEMENT TO SELL ITS RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER TO NOVARTIS Source text for Eikon: Further company coverage:

BRIEF-Ultragenyx And Kyowa Kirin Announce Burosumab Receives Positive CHMP Opinion For Treatment Of X-Linked Hypophosphatemia In Children

* ULTRAGENYX AND KYOWA KIRIN ANNOUNCE BUROSUMAB RECEIVES POSITIVE CHMP OPINION FOR THE TREATMENT OF X-LINKED HYPOPHOSPHATEMIA IN CHILDREN

BRIEF-Ultragenyx And Kyowa Kirin Announce Positive 48-Week Data From Adult Phase 3 Study Of Burosumab In X-Linked Hypophosphatemia

* ULTRAGENYX AND KYOWA KIRIN ANNOUNCE POSITIVE 48-WEEK DATA FROM ADULT PHASE 3 STUDY OF BUROSUMAB (KRN23) IN X-LINKED HYPOPHOSPHATEMIA Source text for Eikon: Further company coverage:

BRIEF-Ultragenyx completes patients dosing in first cohort of phase 1/2 study of DTX301

* Ultragenyx announces completion of patient dosing in first cohort of phase 1/2 clinical study of dtx301 gene therapy in ornithine transcarbamylase (OTC) deficiency

Select another date: